Tumorigenesis requires interactions between tumor progenitors and their microenvironment. We found that low cAMP levels were sufficient for tumorigenesis in a mouse model of Neurofibromatosis-1 (NF1)-associated optic pathway glioma (OPG). We hypothesized that the distinct pattern of glioma in NF1 reflected spatiotemporal differences in CXCL12 effects on cAMP levels. Thus, we sought to alter the pattern of gliomagenesis through manipulation of CXCL12-CXCR4 pathway activation in Nf1 OPG mice. Forced CXCL12 expression induced glioma at a low frequency. Further, treatment of Nf1 OPG mice with AMD3100, a CXCR4 antagonist, did not attenuate glioma growth. Thus, it appears, CXCL12 alone cannot promote gliomagenesis in NF1 mice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910179 | PMC |
| http://dx.doi.org/10.1016/j.jneuroim.2010.05.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Neuro Oncol
November 2024
UCSF Brain Tumor Center, University of California, San Francisco, California, USA.
Article Synopsis
- Glioblastoma, despite treatment advancements, has a poor prognosis with less than 2 years median survival due to the unknown reasons for varied treatment responses.
- A study analyzed glioblastoma samples from 106 patients, identifying early genetic changes like TERT promoter mutations, while later alterations varied between initial and recurrent tumors, along with diverse epigenetic changes impacting treatment outcomes.
- Findings indicated that patients with somatic hypermutation post-treatment had better survival rates, and an epigenomic signature linked to DNA methylation changes could predict clinical results, emphasizing the complex evolution of this cancer.
An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
Invest Ophthalmol Vis Sci
June 2024
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
Optic pathway gliomas (OPGs) are most predominant pilocytic astrocytomas, which are typically diagnosed within the first decade of life. The majority of affected children with OPGs also present with neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome. OPGs in individuals with NF1 primarily affect the optic pathway and lead to visual disturbance.
View Article and Find Full Text PDFThe RAS oncogene in brain tumors and the involvement of let-7 microRNA.
Mol Biol Rep
April 2024
Department of Science, Roma Tre University, Viale Guglielmo Marconi 446, 00146, Rome, Italy.
RAS oncogenes are master regulator genes in many cancers. In general, RAS-driven cancers have an oncogenic RAS mutation that promotes disease progression (colon, lung, pancreas). In contrast, brain tumors are not necessarily RAS-driven cancers because RAS mutations are rarely observed.
View Article and Find Full Text PDFPrevalence of pathogenic germline variants in adult-type diffuse glioma.
Neurooncol Pract
October 2023
Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Background: No consensus germline testing guidelines currently exist for glioma patients, so the prevalence of germline pathogenic variants remains unknown. This study aims to determine the prevalence and type of pathogenic germline variants in adult glioma.
Methods: A retrospective review at a single institution with paired tumor/normal sequencing from August 2018-April 2022 was performed and corresponding clinical data were collected.
Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
Cancer Manag Res
July 2023
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Article Synopsis
- - Optic pathway glioma (OPG) affects about 20% of individuals with neurofibromatosis type 1 (NF1), often resulting in symptoms like vision loss and proptosis, despite many children remaining asymptomatic due to the tumors being usually low-grade and slow-growing.
- - Conventional chemotherapy can slow down OPG growth, but it's unclear if it significantly restores lost vision, and challenges in diagnosing and managing these tumors exist because they mainly impact young children.
- - Recent advancements using genetically engineered mouse models have led to important discoveries about underlying molecular pathways and the identification of potential new treatments, some of which are now in early clinical trials, aiming to enhance risk assessment and treatment for children with NF1-OPG
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!